Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ENTX vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–1 Matrix Metrics)
ENTX Overall Winner
6-Pillar Tally: ENTX 3 – 1 ATYR (2 Tie)
Matrix Metrics: ENTX 5 – 1 ATYR
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. ATYR 34.3/100 SELL) and 1.07β · 46% Vol risk profile, whereas ATYR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ENTX vs ATYR
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.02
+0.17% 1D
Market Cap
$541.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.07β · 46% Vol
Unified Composite Score
53.5
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ATYR
aTyr Pharma, Inc. Common Stock
$4.96
-5.34% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.67β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 1 ATYR)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
ATYR
Revenue Growth (YoY)
-100.0%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
N/A
Market Cap
$541.6M
$15.6M
3. Profitability & Quality
ENTX
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-20.3%
-93.7%
4. Balance Sheet & Cash Flow
ENTX
Cash Generation (TTM)
-$16M
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$265M Net Cash
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
113.8% (32nd %ile)
154.5% (36th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENTX (5) vs ATYR (1)| Institutional Metric | ENTX | ATYR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $541.6M | $15.6M | ENTX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -100.0% | +0.0% | ATYR | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -20.3% | -93.7% | ENTX | |
| 52-Week Range Position | 64% ($1–$4) | 62% ($0–$8) | ENTX | |
| Beta / 30D Volatility | 1.07β · 46% Vol | -9.67β · 13806% Vol | ENTX | |
| Unified Institutional Score | 53.5 / 100 (HOLD) | 34.3 / 100 (SELL) | ENTX | |
| Trailing 12M Revenue (USD) | N/A | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$16M ($265M Net Cash) | N/A ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2785.87 pp
3M Horizon
ATYR +833.66 pp
6M Horizon
ATYR +788.73 pp
1Y Horizon
ATYR +547.08 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | ATYR Revenue | ENTX Op. Margin | ATYR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -5445.0% | ATYR |
| FY2020 | $0M | $10M | -3059.7% | -152.2% | ATYR |
| FY2021 | $0M | N/A | -2139.6% | N/A | ENTX |
| FY2022 | $0M | $10M | -9714.2% | -446.8% | ATYR |
| FY2023 | N/A | $0M | N/A | -15557.8% | ATYR |
| FY2024 | $0M | $0M | -5295.6% | -28899.6% | ENTX |
| FY2025 | $0M | $0M | -27450.0% | -40856.3% | ENTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ENTX
CONSOLIDATION
Current IV
113.8%
IV Percentile
32nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ENTX vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. ATYR 34.3/100 SELL) and 1.07β · 46% Vol risk profile, whereas ATYR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
ATYR leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ENTX cumulative revenue shifted N/A while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
ENTX and ATYR trade at balanced relative valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ATYR vs ENTX · Reverse Pair
ENTX vs IMMP
· Sector Peer
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking